P/B
2,3
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
$971.1M
Market Cap • 10/2/2026
2020
(6 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
Switzerland
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
5
EPS
—
Market Cap
Market Cap
971,1M
EV
535,6M
EV/Revenue
0
EV/EBITDA
-2
EV/EBIT
-2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-32,3%
Total Yield
-32,3%
Payout
0%
Retained Earnings
-594,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,4%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
12,6
Quick Ratio
12
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!